ASRT | tickerfilter.com

Fundamental analysis

44%

Profitability 35%

Dept financing 38%

Liquidity 65%

Performance 48%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.33%

1 Month

-4.10%

3 Months

55.86%

6 Months

2,446.88%

1 Year

2,939.33%

2 Year

1,413.93%

Key data

Stock price

$18.47

P/E Ratio

N/A

DAY RANGE

$18.37 - $18.55

EPS

-$1.99

52 WEEK RANGE

$0.58 - $20.45

52 WEEK CHANGE

$2,939.33

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

6.445 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-05-2025

BETA

1.08

PUBLIC FLOAT

AVERAGE 10 VOLUME

$166,147

AVERAGE 30 VOLUME

$262,256

Company detail

CEO: Daniel A. Peisert
Region: US
Website: assertiotx.com
Employees: 20
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Assertio Holdings, Inc. provides medicines in neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the. treatment of migraine, nausea, photophobia, and phonophobia.

ASRT - Assertio Holdings Inc